

CUMULATIVE INDEX 1994

Volume 15

| | |
|-----------|---|
| March | RESPIRATORY EMERGENCIES I, pages 1-172 |
| June | CLINICAL EXERCISE TESTING, pages 173-451 |
| September | RESPIRATORY EMERGENCIES II, pages 453-606 |
| December | RESPIRATORY DYSFUNCTION IN NEUROMUSCULAR DISEASE, pages 607-810 |

Note: Page numbers of issue and article titles are in **boldface** type.

Abdomen, motion of, analysis of, in ventilatory impairment in neuromuscular disease, 758-759

Abdominal displacement ventilators, in neuromuscular disease, 768-769

Abdominal muscles, 630-631

Abscess, lung, massive hemoptysis due to, 150

Acid maltase deficiency myopathy, respiratory dysfunction in, 667

Acidosis, life-threatening, correction of, in COPD patients with acute respiratory failure, 489 metabolic, exercise in COPD and, 314-315

Acrolein, inhalation injury due to, 113

Acute steroid myopathy, respiratory dysfunction in, 671

Adenosine triphosphate (ATP), in skeletal muscle energetics, 173-176

β -Adrenergic agents, for respiratory failure in COPD, 489-490

β -Adrenergic agonists, for severe asthma, 457-460

Adult respiratory distress syndrome (ARDS), 517-546.
See also *Lung injury, acute*.
causes, 501
clinical course, 523-525
described, 517-518
incidence, 517
outcome following, 523-525
pathophysiology, 519-520

Aerophagia, in COPD patients with acute respiratory failure, 492

Age, of exercise training program participants, 223-224

Air embolism, systemic, 86

Airflow obstruction, in asthma, 455-457

Airway(s), artificial, in mechanical ventilation, 56-59
assessment, in chest trauma, 137-138
iatrogenic complications affecting, upper airway obstruction due to, 39-41

infection of, respiratory failure in COPD due to, 483-484

maintenance of, in acute respiratory failure, 10-11
upper, anatomy of, 35, 36
muscles of, 632-633

Airway management, in respiratory emergencies, 13-34
asthma, 29-30
cricothyroidotomy in, 20-21

general principles, 13-14

massive hemoptysis, 28

medications for, 23-25

percutaneous transtracheal ventilation in, 21-22

special circumstances in, 25-30

surgical routes, 20-23

tracheostomy in, 22-23

translaryngeal intubation, nonsurgical routes, 15-20

trauma, 25-28

upper airway obstruction, 28-29, 46-48

Airway obstruction, in exercise-induced asthma, 352
mechanisms of, 353-355

upper, 35-53
causes, 35, 39-44
clinical evaluation, 38-39
in COPD patients with acute respiratory failure, 486
diagnostic evaluation, 44-46
differential diagnosis, 40
exercise effects, 37-38
fixed, 37
infection and, 43-44
pathophysiology, 35-38
treatment, 28-29, 46-48
nontraumatic, 28-29
variable extrathoracic, 36-37
variable intrathoracic, 37

Airway rewarming, exercise-induced asthma due to, 353-354

Albuterol, for severe asthma, 458-461

Alcohol, acute pulmonary insufficiency due to, 99

Alfentanyl, in airway management, 24

Alveolar-arterial gas exchange, exercise testing effects on, 186-188

Alveolar-arterial oxygen difference: $P(A-a)O_2$, 2-3

Alveolar rupture, mechanical ventilation and, 530-532

Aminophylline, for severe asthma, 460

Amiodarone, respiratory failure due to, 94-95

Ammonia, inhalation injury due to, 105-106

Amniotic fluid embolism, 574-576
described, 574
diagnosis, 575
pathophysiology, 574-575
treatment, 575-576

Amphotericin B, respiratory failure due to, 96

Amyotrophic lateral sclerosis (ALS), described, 675
incidence, 675
pulmonary function testing in, 676-679
respiratory dysfunction in, 675-681
respiratory failure in, 675-676
prevention, 679
treatment, 679
ventilatory support in, 775

Anaerobic threshold, in cardiopulmonary exercise testing, 423-424
noninvasive, 273-275
determination of, methods for, 204

Anemometer, in cardiopulmonary exercise testing, 195

Anesthesia/anesthetics, in airway management, 23-24

Angina, Ludwig's, upper airway obstruction due to, 44

Angioedema, upper airway obstruction due to, 42-43

Anti-inflammatory drugs, nonsteroidal (NSAIDs), for
acute lung injury, 541
respiratory failure due to, 94

Anticholinergic agents, for severe asthma, 460-461

Anticoagulant(s), for pulmonary embolism, 551-552

Antidepressant(s), tricyclic, acute pulmonary insufficiency due to, 99

Aortic insufficiency, in acute cardiogenic pulmonary edema, 507

Aortic stenosis, in acute cardiogenic pulmonary edema, 506-507

ARDS. See *Adult respiratory distress syndrome*.

Arm cranking, 342
upper extremity training with, 343-344

Arm ergometry, 200, 342

Arm exercise, anatomic and mechanical considerations in, 339-341
cardiac and metabolic response to, 342-343
in COPD, 345
gas exchange response in, 343
unsupported, 344-345

Arm exercise testing, 342

Arm training, unsupported, 345-347

Arterial blood gases, in ventilatory impairment in neuromuscular disease, 755

Arterial oxygen saturation, in noninvasive cardiopulmonary exercise, 278

Angiography, in massive hemoptysis, for localization of bleeding, 155
in management, 161-162

Asphyxiants, inhalation injury due to, 110-112

Aspiration, of acid food particles, 125
acid liquid, 121-124
of blood, 125
emergencies related to, 117-135
of gastric contents, 124-125
acute lung injury due to, 522
of hydrocarbons, 125-127
of liquids, 121-127
of nonacid food particles, 125
prevention, 127-128
risk factors for, 117-118, 119
of solid materials, 118-121

Asthma, airway management in, 29-30
death due to, 453
exercise-induced, 351-368
airway obstruction in, 352
causes, 353-355
clinical evaluation, 356
clinical pattern of, 351-352
defined, 351
diagnosis, 356-358
exercise programs in, 362-364

inflammation in, 354-355
late-phase response in, 356
pathophysiology, 351-356
refractory period in, 355-356
symptoms, 351
treatment, 358-362
in difficult-to-manage patients, 361-362
drugs, 359-362
nonpharmacologic, 358-359

fatal, 453, 454

life-threatening, 453-479. See also *Asthma, severe*.
severe, 453-479
clinical assessment, 455-457
epidemiology, 453-455
morbidity and mortality, 473-475
posthospitalization prognosis, 475-476
treatment, 457-475
β-adrenergic agonists, 457-460
aminophylline, 460
anticholinergic agents, 460-461
bronchodilators, 471
buffer therapy, 471-472
complications, 473-476
corticosteroids, 461-463
endotracheal intubation, 463-465
magnesium sulfate, 463
mechanical ventilation, 465-469
nonventilator, 469-473
sedation, 469-471
unconventional, 472-473
severity of, increase in, 453

Asynchrony, respiratory distress due to, 61-62

Atropine methonitrate, for respiratory failure in COPD, 490

Auto-PEEP, mechanical ventilation and, 62-64

Balke protocol, in cardiopulmonary exercise testing, 198-199

Balloon tamponade, in massive hemoptysis management, 159

Barbiturate(s), acute pulmonary insufficiency due to, 99

Barotrauma, 75, 86-88
clinical forms of, 75
defined, 75
management, 88-89
mechanical ventilation and, 64-65, 530-532

Benzodiazepine(s), in airway management, 24

Beta-adrenergic agents, in exercise-induced asthma, 359-360

Beta-blockers, respiratory failure due to, 95

Bleeding, gastrointestinal, 492-493

Bleomycin, respiratory failure due to, 96

Blood, aspiration of, 125

Blood gas(es), arterial, in exercise testing in pulmonary patients, 335
changes in, exercise in patients with lung disease and, 332-333
exercise in COPD and, 313-314

Blood gas analysis, arterial, in asthma, 457
in respiratory failure, 482
in Guillain-Barré syndrome, 708-710

Blood lactate levels, in exercise training program, 222

Blood pressure response, in noninvasive cardiopulmonary exercise testing, 275-277

Botulism, poisoning due to, 100

Brainstem, and neuromuscular disease, 614
strokes of, 730-731

Breath-by-breath analysis, in cardiopulmonary exercise testing, 197

Breathing, difficult. See *Dyspnea*.

disorders of, sleep-related, in ventilatory impairment in neuromuscular disease, 752

efficiency of, 625

impediment to, during exercise, 250-252

in myasthenia gravis, 685

ventilation in, 607-609

work of, 625

Breathing patterns, abnormal, CNS injury and, 741-742

in cardiopulmonary exercise testing, 426-427

during exercise, in the elderly, 232-233

in interstitial lung disease, 288-290

exercise in COPD and, 309-310

Breathing reserve, in cardiopulmonary exercise testing, 207-208, 425-426

Breathlessness. See *Dyspnea*.

Bromocriptine, pleuropulmonary disease due to, 724

Bronchial irrigation, in massive hemoptysis management, 158

Bronchiectasis, massive hemoptysis due to, 149

Bronchitis, acute, respiratory failure in COPD due to, 483-484

Bronchoalveolar lavage (BAL), quantitative culture of, in nosocomial pneumonia diagnosis, 595-596

Bronchodilator(s), for respiratory failure in COPD, 489-490

for severe asthma, 471

Bronchography, for localization of bleeding in massive hemoptysis, 155-156

Bronchoscopic dilatation, in upper airway obstruction, 48

Bronchoscopy, in massive hemoptysis, for localization of bleeding, 154-155

in management, 158-159

Bronchospasm, exercise-induced, 333

Bruce protocol, in cardiopulmonary exercise testing, 198

Buffer therapy, for severe asthma, 471-472

Cadmium, inhalation injury due to, 109-110

Calcium channel blockers, in exercise-induced asthma, 361

Carbon dioxide, exercise training effects on, 218

role during exercise, 249

in skeletal muscle energetics, 175-176

Carbon dioxide ventilatory response, evaluation, 610

Carbon monoxide, inhalation injury due to, 110-111

Cardiac injuries, diagnosis and treatment, 143

Cardiac massage, closed-chest, for venous air embolism, 573

Cardiac output, optimization of, in acute lung injury, 539

Cardiac tamponade, in chest trauma, 140-141

Cardiopulmonary exercise testing, 193-213. See also *Exercise testing, cardiopulmonary*.

Cardiopulmonary system, exercise effects on, 305-306

Cardiorespiratory disorders, dyspnea effects on, 253-254

Cardiovascular disease, cardiopulmonary exercise testing in, 271-285

anaerobic threshold, 273-275

arterial oxygen saturation, 278

blood pressure response, 275-277

chronotropic dysfunction evaluation, 282-283

clinical applications of, 279-284

in diastolic dysfunction, 280

in heart failure, 280

heart rate response, 275-277

in heart transplantation, 280-282

invasive, 278-279

maximal oxygen uptake, 271-273

noninvasive, 271-278

oxygen pulse, 277

in pulmonary hypertension, 283-284

in pulmonary vascular disease, 283-284

in systolic dysfunction, 279-280

ventilation measurements, 278

Cardiovascular system, assessment, in chest trauma, 138-141

exercise testing effects on, 176-180

Catheter(s), Swan-Ganz, for acute lung injury, 538-539, 541

tracheal, upper airway obstruction due to, 41

Catheterization, cardiac, invasive, in lung resection evaluation, 390-391

pulmonary artery, in acute cardiogenic pulmonary edema, 507-508

Central nervous system (CNS), trauma to, management, 743-746

normal respiratory control and, 740-741

respiratory complications of, 741-743

respiratory dysfunction associated with, 739-749

epidemiology, 739-740

Cervical spine injury, airway management in, 25-26

Chest trauma, 137-146

airway management in, 27-28

assessment, airway, 137-138

of cardiovascular function, 138-141

initial, 137

chest wall injuries, 142-143

crush injury, diagnosis and treatment, 143

flail chest, 142-143

incidence, 137

pneumothorax in, 138

types, 141-145

Chest wall, injuries of, diagnosis and treatment, 142-143

Chlorine, inhalation injury due to, 106

Chronic obstructive pulmonary disease (COPD), acute respiratory failure in, 481-500

airway infection and, 483-484

airway obstruction due to, 486

assessment, 481-482

causes, 482-486

complications, 492-493

dysrhythmias in, 492

ethical and societal issues related to, 496-497

fluid status assessment, 485

heart function assessment, 485

management, 482, 486-495

mechanical ventilation for, 493-495

natural history of, 495-496

patient noncompliance and, 486

pleural effusions and, 486

prognosis, 495-496

pulmonary embolism and, 484

rib fractures and, 486

spontaneous pneumothorax and, 486

exercise in, 305-326

arm, 345

blood gases, 313-314

breathing pattern, 309-310

contraction patterns of respiratory muscles, 312-313

heart function, 314

inspiratory muscle fatigue, 313

inspiratory muscle function, 311-312

metabolic acidosis, 314-315

metabolic rate, 306-308

pulmonary mechanics, 310-311

ventilation, 308-309

exercise intolerance in, 305

Chronic obstructive pulmonary disease (COPD) (Continued)

- exercise limitation in, 316-319
- exercise physiology in, 306-319
- exercise testing in, 319-323
 - interpretation of, 321-323
 - methods, 320-321
 - protocols for, 320
 - purpose of, 319-320
 - reproducibility of variables during, 320
 - safety of, 321
 - uses, 319
- incidence, 481
- spontaneous pneumothorax in, 79-80

Chronotropic dysfunction, evaluation, 282-283

Circulation, respiratory muscle effects on, 626-627

CNS. See *Central nervous system*.

Coagulants, topical, in massive hemoptysis management, 159

Cocaine, respiratory insufficiency due to, 97-98

Colchicine, acute pulmonary insufficiency due to, 99

Colloid(s), for acute lung injury, 538

Computed tomography (CT), for localization of bleeding in massive hemoptysis, 156-157

- upper airway obstruction due to, 45

Condensate, respiratory distress due to, 60

Congenital myopathies, respiratory dysfunction in, 666-667

Congenital myotonic dystrophy, respiratory dysfunction in, 666

Congestion, pulmonary, during exercise, in the elderly, 240

Contrast media, respiratory failure due to, 96

Controlled hypoventilation, 465

Conventional tomography, upper airway obstruction due to, 45

COPD. See *Chronic obstructive pulmonary disease*.

Corticosteroid(s), for acute lung injury, 541

- in exercise-induced asthma, 361
- in fat embolism syndrome, 566-568
- in respiratory failure in COPD, 491
- in severe asthma, 461-463
- in upper airway obstruction, 47

Cough, respiratory distress due to, 58

- stroke and, 734
- in ventilatory impairment in neuromuscular disease, 752

Craniofacial trauma, airway management in, 26-27

Cricothyroidotomy, in airway management, 20-21

Cromolyn, in exercise-induced asthma, 360

Croup, upper airway obstruction due to, 43

Cyanide, hydrogen inhalation injury due to, 111-112

- poisoning by, treatment, 111

Cycle ergometer, in cardiopulmonary exercise testing, 193-194

- protocols in, 199-200

Cycle ergometry, arm, 342

Cystic fibrosis, massive hemoptysis due to, 152

Cytosine arabinoside, respiratory failure due to, 95

"Deep sulcus sign," 531

Dextran, respiratory failure due to, 96

Diaphragm, injuries to, diagnosis and treatment, 145

- paralysis of, in ventilatory impairment in neuromuscular disease, 754

Diaphragm motor unit, activity of, muscle fiber properties affected by, 648-653

- inactivity of, motoneuronal properties affected by, 655

neuromuscular junction affected by, 653-655

innervation of, muscle fiber properties affected by, 648

muscle fiber type composition of, 646-647

physiology, 642-644

recruitment, 644-646

Diaphragm muscle, 627-629

- activation pattern of, physiologic effects, 641
- denervation of, 641-659
- myosin heavy chain phenotype, 647-648
- weakness of, evaluation, 676

Diastolic dysfunction, cardiopulmonary exercise testing for, 280

- described, 506

Diazepam, in airway management, 24

Diffusing capacity, in lung resection evaluation, 390

Diffusion, abnormal, in acute respiratory failure, 7

Disability, impairment versus, 370-371

Disability evaluation, exercise testing in, 369-387. See also *Impairment evaluation, exercise testing in*.

Diuretic(s), thiazide, respiratory failure due to, 95

L-Dopa, for Parkinson's disease, respiratory dysfunction due to, 721-724

Drowning, incidence, 128

Drug(s), for acute lung injury, 539-541

- acute lung injury due to, 522-523
- in airway management, 23-25
- in exercise-induced asthma, 359-362
- hypoventilation due to, 97
- neuromuscular blockade due to, 97
- overdose of, acute pulmonary insufficiency due to, 98-99

respiratory failure due to, 93-102

- amiodarone, 94-95
- amphotericin B, 96
- beta-blockers, 95
- bleomycin, 96
- contrast agents, 96
- cytosine arabinoside, 95
- dextran, 96
- insulin, 97
- interleukin-2, 97
- intravenous hydrocortisone, 94
- methotrexate, 95-96
- naloxone, 94
- neuromuscular blockade, 96
- nitrofurantoin, 96
- NSAIDs, 94
- penicillamine, 95
- protamine, 95
- salicylates, 94
- thallium-dipyridamole imaging, 97
- thiazide diuretics, 95
- tocolytics, 95

respiratory insufficiency due to, 97-98

Drug abuse, pneumothorax-associated with, 80

Duchenne muscular dystrophy, advanced stages of, 664-665

- P₀ in, 612-613

respiratory dysfunction in, 663-665

- ventilatory support in, 774-775

Dynamic hyperinflation, 466-468

- mechanical ventilation and, 62-64

Dyspnea, in acute lung injury, 520

- in asthma, 455-456
- in cardiopulmonary exercise testing, 430
- cause, 248
- defined, 247
- exertional, assessment, 254-255
- cardiac disease related to, 262-263
- causes, 260

characteristics, 261
 clinical evaluation, 259-269
 described, 248-249, 261
 in the elderly, 239
 in interstitial lung disease, 291
 laboratory testing in, 262-264
 limitation in cardiorespiratory disorders due to, 253-254
 mechanisms of, 247-257
 medical history in, 259-262
 physical examination in, 262
 respiratory disease related to, 263-264
 systems analysis of, 249-252
 unexplained, 264
 measurement of, during exercise, 265-267
 mechanisms in, 247-248
 sensory limitation to, 252-253
 in ventilatory impairment in neuromuscular disease, 752, 760

Dysrhythmia(s), in COPD patients with acute respiratory failure, 492

Dystrophy(ies), facioscapulohumeral, respiratory dysfunction in, 666
 limb girdle, 666
 muscular. See *Muscular dystrophies*.
 myotonic, congenital, respiratory dysfunction in, 666
 respiratory dysfunction in, 665-666

ECG. See *Electrocardiogram*.
 Edema, glottic, intubation and, 40
 pulmonary. See *Pulmonary edema*.
 Elderly, exercise in, practical considerations concerning, 243-244
 pulmonary system's response to, 229-246. See also *Pulmonary system, exercise effects on, in the elderly*.
 structural and functional changes in, 230-231

Electrocardiogram (ECG), in cardiopulmonary exercise testing, 207
 in exercise testing in pulmonary patients, 334-335

Electrolyte disorders, respiratory dysfunction in, 671

Electromyography (EMG), in respiratory muscle evaluation, 610

Electronic signals, processing of, in cardiopulmonary exercise testing, 195-197

Embolectomy, for pulmonary embolism, 556

Embolism, amniotic fluid, 574-576
 pulmonary, respiratory failure in COPD due to, 484
 tumor, 568-569
 venous air, 570-574. See also *Venous air embolism*.

Embolotherapy, in massive hemoptysis management, 161-162

Emphysema, pulmonary interstitial, 86
 subcutaneous, 86

Encephalitis lethargica, 715

Endobronchial blockade, in massive hemoptysis management, 159-161

Endocrine myopathies, respiratory dysfunction in, 670-671

Endotracheal cuff, failure of, respiratory distress due to, 57-58

Endotracheal intubation, for Guillain-Barré syndrome, 710-711

Endotracheal tube, double-lumen, in massive hemoptysis management, 160-161
 failure of, respiratory distress due to, 57-58
 malposition of, respiratory distress due to, 56-57

Endurance training, purpose of, 215

Epiglottis, upper airway obstruction due to, 43-44

Epinephrine, in massive hemoptysis management, 158
 racemic, in upper airway obstruction, 47
 for severe asthma, 457-458

Equipment, in cardiopulmonary exercise testing, 193-195

Ergometry, arm, 200

Ergot derivatives, pleuropulmonary disease due to, 724

Esophagus, injuries to, diagnosis and treatment, 145

Ethical issues, in long-term ventilatory support, 787-789

Ethylchlorvynol, respiratory insufficiency due to, 98

Exercise, arm, 339-349. See also *Arm exercise*.
 asthma and, 351-368. See also *Asthma, exercise-induced*.
 carbon dioxide's role during, 249
 cardiorespiratory responses to, 305-306
 in COPD, 305-326. See also *Chronic obstructive pulmonary disease, exercise in*.
 dyspnea during, measurement of, 265-267
 in the elderly, practical considerations concerning, 243-244
 intensity of, domains of, 189-191
 in exercise training program, 220-221
 in interstitial lung disease, breathing pattern, 288-290
 dyspnea, 291
 gas exchange, 291-292
 heart function, 292
 mechanics of, 290-291
 physiology of, 287-296
 respiratory muscles, 292-294
 ventilation, 288-290
 oxygen delivery during, 249
 in pulmonary rehabilitation, 327-337. See also *Pulmonary rehabilitation, exercise in*.
 pulmonary system's effects of, in the elderly, 229-246. See also *Pulmonary system, exercise effects on, in the elderly*.
 in young adults, 229-230
 respiratory muscle weakness and fatigue during, 252
 upper airway obstruction effects of, 37-38
 upper extremity, clinical use of, 339-349. See also *Arm exercise*.
 ventilatory demands of, 249-252

Exercise intolerance, in COPD, 305
 described, 173

Exercise limitation, in cardiopulmonary exercise testing, 430
 in lung and heart-lung transplant recipients, 416-418
 Exercise performance, pulmonary system's limitations to, in the elderly, 241-243

Exercise testing, alveolar-arterial gas exchange in, 186-188
 bioenergetic and gas exchange basis of, 173-192
 cardiopulmonary, 193-213
 abnormalities in, patterns of, 430-431
 anaerobic threshold in, 204-207
 breath-by-breath analysis, 197
 breathing reserve in, 207-208
 cardiopulmonary measurements in, 194-195
 in cardiovascular disease, 271-285. See also *Cardiovascular disease, cardiopulmonary exercise testing in*.
 conduct of, 200-203
 contraindications, 201
 ECG in, 207
 electronic signals in, processing of, 195-197
 equipment for, 193-195
 calibration of, 194
 exercise limitation in, 430
 integrative, 371-373
 interpretation of, 421-445
 abnormalities in, 430-431
 anaerobic threshold in, 423-424
 breathing patterns in, 426-427

Exercise testing (Continued)
 breathing reserve in, 425-426
 case studies, 431-443
 dyspnea in, 430
 heart rate in, 424-425
 maximum aerobic capacity in, 421-422
 measurements and relationships in, 421-425
 pulmonary gas exchange in, 427-430
 respiratory factors in, 425
 invasive versus noninvasive, 200
 in lung and heart-lung transplantation, 405-420. See also *Heart-lung transplantation; Lung transplantation, exercise testing in*.
 measurements during, 203-207
 mechanical simulator in, 198
 metabolic measurements in, equipment for, 194-195
 mixed chamber in, 197
 normal reference values in, 209-210
 oxygen pulse in, 207
 physiologic validation in, 198
 preliminary requirements for, 201
 procedure for, 201-202
 protocols in, 198-200
 quality assurance in, 197-198
 cardiovascular responses to, 176-180
 in COPD, 319-323. See also *Chronic obstructive pulmonary disease, exercise testing in*.
 exercise intensity domains in, 189-191
 gas exchange in, 181-184
 in impairment and disability evaluation, 369-387. See also *Impairment evaluation, exercise testing in*.
 in interstitial lung disease, 287-303. See also *Lung disease(s), interstitial, exercise testing in*.
 issue on, 173-174
 lactate threshold in, 177, 178, 180-181
 in lung resection evaluation, 393-400
 in pulmonary rehabilitation, 328-333
 purpose of, 215
 ventilatory requirements in, 184-186
 Exercise tolerance, of COPD patients, 329-330
 Exercise training, carbon dioxide effects of, 218
 oxygen uptake effects of, 216-220
 physiologic responses to, 215-227
 mechanisms of, 220
 program for. See *Exercise training program*.
 in pulmonary rehabilitation, 327-337
 pulmonary ventilation effects of, 218
 structural and biochemical changes induced by, 215-216
 types, 215
 Exercise training program, age of participants in, 223-224
 blood lactate levels in, 222
 characteristics, 220-225
 designing of, 224
 duration of, 223
 in exercise-induced asthma, 362-364
 exercise intensity of, 220-221
 gender of participants in, 224
 and health, 225
 heart rate in, 221-222
 level of fitness in, 223
 maintaining fitness through, 224-225
 modes of exercise, 223
 oxygen uptake in, 222
 sessions in, duration of, 223
 frequency of, 223
 Exercise training response, in pulmonary rehabilitation, 328
 Expiratory muscle(s), described, 340-341

Expired gas analysis, in exercise testing in pulmonary patients, 335
 Extracorporeal membrane oxygenation (ECMO), for acute lung injury, 535-536
 Extremities, upper, exercise of, clinical use of, 339-349

Faciocapulohumeral muscular dystrophy (FSH),
 respiratory dysfunction in, 666
 ventilatory responses in, 613
 Fast twitch, 173
 Fat embolism syndrome, 561-568
 clinical features, 562-563
 clinical manifestations, 562-565
 dermatologic manifestations, 565
 diagnosis, 565-566
 incidence, 562
 neurologic abnormalities in, 563
 pathogenesis, 565
 respiratory impairment in, 563-565
 treatment, 566-568
 Fatigue, respiratory muscle, 624-625
 Fenoterol, for severe asthma, 460-461
 Fentanyl, in airway management, 24
 Fiber(s), in skeletal muscles, 622
 type I, 173-174
 in exercise training, 216
 type II, 174
 in exercise training, 216
 Fistula, tracheoesophageal, respiratory distress due to, 58
 Fitness, maintenance of, through exercise training program, 224-225
 Flail chest, diagnosis and treatment, 142-143
 Flow meters, in cardiopulmonary exercise testing, 195
 Flow-volume loops, abnormalities of, in ventilatory impairment in neuromuscular disease, 756
 Fluid status, assessment, in COPD patients with acute respiratory failure, 485
 Fluids, for ARDS, 536-538
 Flumazenil, in airway management, 24
 Foreign body aspiration, emergencies related to, 117-135. See also *Aspiration*.
 radiographic findings in, 120
 upper airway obstruction due to, 42
 Fracture(s), rib, in COPD patients with acute respiratory failure, 486
 diagnosis and treatment, 142
 sternal, diagnosis and treatment, 142
 Fuel cell analyzers, in cardiopulmonary exercise testing, 195
 Functional stridor, upper airway obstruction due to, 41
 Fungal infection, massive hemoptysis due to, 150

Gas(es), respiratory, irritant, inhalation injury due to, 103-110
 sources of exposure to, 104
 Gas analyzers, in cardiopulmonary exercise testing, 195
 Gas exchange, during exercise, in the elderly, 237-238
 in interstitial lung disease, 291-292
 exercise testing effects on, 181-184
 physiology of, 1-2
 pulmonary, in cardiopulmonary exercise testing, 208-209
 Gastric distention, in COPD patients with acute respiratory failure, 492-493
 Gastrointestinal bleeding, in COPD patients with acute respiratory failure, 492-493

Gender, of exercise training program participants, 224
 Great vessel trauma, diagnosis and treatment, 143-144
 Guillain-Barré syndrome, described, 705
 incidence, 705
 respiratory failure in, 706-707
 respiratory function in, assessment, 707-710
 disorders of, 705-714
 management, 710-712
 treatment, 712-713
 ventilatory support in, 776

Haemophilus influenzae, respiratory failure in COPD due to, 483-484
 HAP, 509-512
 Head injuries, respiratory care in, 743-744
 Health, exercise training and, 225
 Heart, function of, exercise in COPD and, 314
 exercise in interstitial lung disease and, 292
 transplantation of, cardiopulmonary exercise testing for, 280-282
 Heart disease, congenital, massive hemoptysis due to, 150-151
 exertional dyspnea and, 262-263
 valvular, pulmonary edema due to, 506-507
 Heart failure, cardiopulmonary exercise testing for, response to, 282
 chronic, cardiopulmonary exercise testing for, 280
 Heart function, assessment, in COPD patients with acute respiratory failure, 485
 Heart-lung transplantation, exercise limitation in, 416-418
 exercise testing in, 415-416
 guidance provided by, 418-419
 Heart rate, in cardiopulmonary exercise testing, 424-425
 noninvasive, 275-277
 in exercise training program, 221-222
 Heat loss, exercise-induced asthma due to, 353-354
 Helium-oxygen, in upper airway obstruction, 47-48
 Hemlock, poisoning due to, 100
 Hemoptysis, cryptogenic, 154
 iatrogenic, 152
 massive, 147-168
 airway management in, 28
 alveolar hemorrhage and, 152
 autoimmune disease and, 152
 bronchiectasis and, 149
 causes, 148-154
 cystic fibrosis and, 152
 defined, 28, 147
 described, 147
 fungal infection and, 150
 localization of the bleeding site in, 154-157
 lung abscess and, 150
 management, 157-163
 mitral stenosis/congenital heart disease and, 150-151
 outcome, 163-164
 tuberculosis and, 148-149
 tumors and, 151-152
 vascular anomalies and, 152, 154
 Hemorrhage, alveolar, massive hemoptysis due to, 152
 Hemothorax, in chest trauma, 139-140
 Heparin, for pulmonary embolism, 551-552
 Heroin, respiratory insufficiency due to, 98
 Hiccup, stroke and, 734
 in ventilatory impairment in neuromuscular disease, 754
 Hot-wire, in cardiopulmonary exercise testing, 195

Hydrocarbon ingestion, 125-127
 Hydrocortisone, intravenous, respiratory failure due to, 94
 for severe asthma, 461-463
 Hydrogen chloride, inhalation injury due to, 106-107
 Hydrogen cyanide, inhalation injury due to, 111-112
 Hydrogen fluoride, inhalation injury due to, 106-107
 Hydrogen sulfide, inhalation injury due to, 112
 Hyperadrenocorticism, respiratory dysfunction in, 671
 Hypercapnia, unexplained, in ventilatory impairment in neuromuscular disease, 760-761
 Hyperinflation, dynamic (DHI), 466-468
 Hypertension, pulmonary, cardiopulmonary exercise testing for, 283-284
 Hyperventilation, for head and spinal cord injuries, 744
 Hypocapnia, in asthma, 457
 Hypotension, in pulmonary embolism, 556-557
 Hypothyroidism, respiratory dysfunction in, 670-671
 Hypoventilation, in acute respiratory failure, 4
 central, drugs associated with, 97
 controlled, 465
 Hypoxemia, arterial, CNS injury and, 741
 in asthma, 457
 correction of, in COPD patients with acute respiratory failure, 487-489

Ileus, intestinal, in COPD patients with acute respiratory failure, 492-493
 Impairment, disability versus, 370-371
 Impairment evaluation, exercise testing in, 369-387
 application of, examples, 381-384
 integrative cardiopulmonary, 378-381
 physiologic basis for, 373-377
 recommendations for, 384-385
 Infection(s), acute lung injury and, 522
 airway, respiratory failure in COPD due to, 483-484
 fungal, massive hemoptysis due to, 150
 nosocomial, in COPD patients with acute respiratory failure, 493
 upper airway obstruction due to, 43-44
 Inferior vena cava (IVC) filter, for pulmonary embolism, 555-556
 Inflammation, exercise-induced asthma due to, 354-355
 Inflammatory myopathies, respiratory dysfunction in, 669-670
 Informed consent, for respiratory care in neuromuscular disease, 789-790
 Infrared analyzer, in cardiopulmonary exercise testing, 195
 Inhalation injury, acute, 103-116
 asphyxiants and, 110-112
 irritant gases and, 103-110
 smoke inhalation and, 112-114
 systemic toxins and, 112
 upper airway obstruction due to, 41-42
 Inhaler(s), metered dose (MDI), for respiratory failure in COPD, 489-490
 Inspiratory muscle(s), accessory, described, 340
 Inspissated secretions, respiratory distress due to, 57
 Insulin, respiratory failure due to, 97
 Intensive care unit (ICU), for respiratory failure in COPD, 486-487
 Intercostal muscles, 630
 Interleukin-2, respiratory failure due to, 97
 Intestinal ileus, in COPD patients with acute respiratory failure, 492-493
 Intubation, difficult, 17-18
 endotracheal, complications, 18-20

Intubation (Continued)

- for Guillain-Barré syndrome, 710-711
- route selection for, 16-17
- tube position in, 17
- nasotracheal, 15-16
- orotracheal, 15
- tracheal, airway injury following, 39-41
- tracheal stenosis due to, 39
- translaryngeal, airway injury following, 39
- complications, 18-20
- nonsurgical routes, 15-20
- types, 15-18

Ipratropium, in exercise-induced asthma, 361

- for respiratory failure in COPD, 490
- for severe asthma, 460-461

Isoproterenol, for severe asthma, 457-458

Kyphoscoliosis, 774

Lactate threshold, 180-181

- indices of, 177, 178

Laryngospasm, intubation and, 40-41

Laryngotracheal resection and reconstruction, in upper airway obstruction, 48

Laryngotracheobronchitis, upper airway obstruction due to, 43

Laser therapy, in upper airway obstruction, 48

Latissimus dorsi muscle, 632

Legal issues, in long-term ventilatory support, 787-789

Levator costarum muscles, 632

Lidocaine, in airway management, 23-24

Limb girdle dystrophy, respiratory dysfunction in, 666

Ludwig's angina, upper airway obstruction due to, 44

Lung(s), function of, in lung disease, 376-377

- predicting exercise performance from, 374-376
- mechanics of, exercise in COPD and, 310-311
- vascular anatomy of, 147-148

Lung abscess, massive hemoptysis due to, 150

Lung disease(s), diffusing capacity in, 377

- exercise capacity in, 376-377
- exercise gas exchange in, 377
- exercise in, blood gas changes due to, 332-333
- interstitial, exercise limitation in, 294-296
- exercise performance in, therapeutic modalities to alter, 299-300
- exercise testing in, 287-303
- clinical uses, 296-297
- conduct and interpretation of, 297-299
- physiology of, 287-296

leading to impairment from occupational injury, 373

pulmonary function in, 376-377

Lung injury, acute, 517-546. See also *Adult respiratory distress syndrome*.

- causes, 521-523
- clinical course, 523-525
- clinical evolution of, 520
- defined, 518
- drug-induced, 522-523
- management, 525-541
- colloids, 538
- corticosteroids, 541
- drugs, new, 539-541
- fluids, 536-538
- goals of, 525
- hemodynamic support, 536-539
- NSAIDs, 541

oxygenation and ventilatory support, 528-536

- prostaglandin E₁, 540
- Swan-Ganz catheters, 538-539
- of underlying illness, 526-528
- outcome following, 523-525
- pathophysiology, 519-520
- PEEP in, 528-530
- predisposing conditions, 521-523
- prognostic factors in, 523
- risk factors for, 521-523
- mechanical ventilation and, 530

Lung resection, evaluation, 389-403

- diffusing capacity in, 390
- exercise testing in, 393-400
- "high-tech," 397-400
- incremental, 397-399
- "low-tech," 395-397
- methods, 395
- submaximal, 399-400
- invasive cardiac catheterization in, 390-391
- risk stratification analysis in, 392-393
- spirometry in, 389-390
- split lung function studies in, 391-392

Lung score, components of, 518

Lung transplantation, exercise limitation in, 416-418

- exercise testing in, 405-420
- bilateral-lung, 408, 411-415
- guidance provided by, 418-419
- single-lung, 407-408, 409, 410
- at Washington University/Barnes Hospital, 406-415

Lymphomatosis, intravascular, 569-570

Magnesium sulfate, for severe asthma, 463

Magnetic resonance imaging (MRI), upper airway obstruction due to, 45-46

Mass spectrometer, in cardiopulmonary exercise testing, 195

Massive hemoptysis, 147-168. See also *Hemoptysis, massive*.

Maximal oxygen consumption, in cardiopulmonary exercise testing, 203-204

defined, 203

Maximal voluntary ventilation, in ventilatory impairment in neuromuscular disease, 756

Mechanical simulator, in cardiopulmonary exercise testing, 198

Mechanical ventilation, in Guillain-Barré syndrome, 711

Metabolic acidosis, exercise in COPD and, 314-315

Metabolic myopathies, respiratory dysfunction in, 667-668

Metabolic rate, exercise in COPD and, 306-308

Metered-dose inhaler (MDI), for respiratory failure in COPD, 489-490

Methadone, respiratory insufficiency due to, 98

Methane, inhalation injury due to, 110

Methotrexate, respiratory failure due to, 95-96

Methylprednisolone, for fat embolism syndrome, 566

- for respiratory failure in COPD, 491
- for severe asthma, 461-462

Midazolam, in airway management, 24

Mitochondrial myopathies, respiratory dysfunction in, 667-668

Mitral insufficiency, in acute cardiogenic pulmonary edema, 507

Mitral stenosis, massive hemoptysis due to, 150-151

Mixing chamber, in cardiopulmonary exercise testing, 197

Mouth occlusion pressure, evaluation, 610

Mucus, secretion of, alterations in, 742

Multiple sclerosis, described, 693
prevalence, 693
pulmonary edema in, 698-699
respiratory dysfunction in, 693-693
monitoring of, 699-700
treatment, 700-702

respiratory involvement in, 693-698
ventilatory support in, 776

Multiple system atrophy, 720

Muscle(s), abdominal, 630-631
in exercise testing in pulmonary patients, neural control and coordination of, 341-342

expiratory, described, 340-341

fiber-type composition of, 181

inspiratory, accessory, described, 340
fatigue of, exercise in COPD and, 313

intercostal, 630

latissimus dorsi, 632

levator costarum, 632

metabolism of, during exercise, 249-250

parasternal, 629-630

pectoralis major, 631-632

respiratory. *See Respiratory muscle(s)*.

scalene, 629

skeletal, contractile cells in, 216
energetics of, 173-176
in exercise training, 215-227

sternomastoid, 630

triangularis sterni, 631-632

upper airway, 632-633

weakness of, in ventilatory impairment in neuromuscular disease, 752-753

Muscle contraction, respiratory, inappropriate, syndromes of, 754-755

Muscle relaxant(s), in airway management, 24-25

Muscular dystrophies, Duchenne. *See Duchenne muscular dystrophy*.

facioscapulohumeral, ventilatory responses in, 613

oculopharyngeal, 666

ventilatory support in, 773-775

Mushrooms, poisoning due to, 100

Myasthenia gravis, classification of, 686
clinical features, 685
described, 683
diagnosis, 687
differential diagnosis, 687-688
pathophysiology, 683
prevalence, 685
respiratory dysfunction in, 683-691
assessment, 688
management, 688-689
respiratory system involvement in, 683-685
systems affected by, 685-686
ventilatory support in, 775-776

Mycoplasma pneumoniae, respiratory failure in COPD due to, 484

Myocardial contusion, diagnosis and treatment, 143

Myopathy(ies), acute steroid, respiratory dysfunction in, 671
congenital, respiratory dysfunction in, 666-667
endocrine, respiratory dysfunction in, 670-671
inflammatory, respiratory dysfunction in, 669-670
metabolic, respiratory dysfunction in, 667-668
mitochondrial, respiratory dysfunction in, 667-668
progressive, ventilatory support in, 773-775
and sleep disorders, 662

Myosin heavy chain phenotype, in diaphragm muscle, 647-648

Myotonic dystrophy, respiratory dysfunction in, 665-666

Naloxone, respiratory failure due to, 94

Near-drowning, 128-130

Nebulizer(s), in-line, respiratory distress due to, 59-60

Nedocromil, in exercise-induced asthma, 360

Negative pressure ventilation, in neuromuscular disease, 767-768

Neuromuscular blockade, drugs causing, 97
respiratory failure due to, 96

Neuromuscular disease, abdominal displacement ventilators in, 768-769

brainstem and, 614

diffuse, 753-754

mechanical ventilation in, 765-781

negative pressure ventilation in, 767-768

positive pressure ventilation in, 765-767

respiratory dysfunction in, issue on, 607-795
long-term care, 784-787

management, 783-795
life-sustaining, refusal of, 790
right to refuse, 790-791

mechanical ventilation for, withdrawal of, 791-792

rehabilitation for, 784-787

surrogate decision-making in, 792-793

respiratory muscle disorders due to, 619-639

sleep and, 613-614

ventilation in, central control of, 607-617
laboratory evaluations in, 609-610

ventilator selection in, 771-772

ventilatory control in, measures of, 613

ventilatory function in, assessment, 751-763. *See also Ventilatory failure, assessment, in neuromuscular disease*.

ventilatory response in, 611-612

Nitrofurantoin, respiratory failure due to, 96

Nitrogen dioxide, inhalation injury due to, 107-108

Noncompliance, respiratory failure in COPD due to, 486

Nosocomial infections, in COPD patients with acute respiratory failure, 493

NSAIDs. *See Anti-inflammatory drugs, nonsteroidal*.

Nuclear imaging studies, for localization of bleeding in massive hemoptysis, 157

Oculopharyngeal muscular dystrophy, respiratory dysfunction in, 666

Ondine's syndrome, 731-733

Opioids, in airway management, 24

Organophosphate(s), poisoning due to, 99-100

Oxidation, substrate, oxygen and carbon dioxide demands of, 175

Oximetry, pulse, in cardiopulmonary exercise testing, 202-203

Oxygen, inspired, reduction of, in acute respiratory failure, 7-8
reduced requirements for, in acute respiratory failure, 11
role during exercise, 249
in skeletal muscle energetics, 175-176

Oxygen pulse, in cardiopulmonary exercise testing, 207 noninvasive, 277

Oxygen therapy, in acute respiratory failure, 11

Oxygen transport, respiratory failure effects on, 11

Oxygen uptake, exercise training effects on, 216-220
in exercise training program, 222
maximal, in noninvasive cardiopulmonary exercise testing, 271-273

Oxygen ventilatory response, evaluation, 609

Oxyhemoglobin saturation, in ventilatory impairment in neuromuscular disease, 755

Ozone, inhalation injury due to, 108

P_{CO₂}, and neuromuscular disease, 612-613

Pain, respiratory distress due to, 58

Pancuronium, in airway management, 24

Paralysis, diaphragmatic, in ventilatory impairment in neuromuscular disease, 754

 periodic, respiratory dysfunction in, 668-669

 for severe asthma, 469-471

Paralysis agitans, 715

Paramagnetic analyzer, in cardiopulmonary exercise testing, 195

Paraquat, poisoning due to, 99

Parasternal muscles, 629-630

Parkinsonism, 715

 idiopathic, 719-720

 postencephalic, 720-721

Parkinson's disease, clinical features, 715

 pulmonary mechanics in, 716-718

 respiratory dysfunction in, 715-727

 medications and, 721-724

 ventilatory support in, 777

Patient autonomy, for respiratory care in neuromuscular disease, 789-790

Pectoralis major muscle, clavicular head of, 631-632

Penicillamine, respiratory failure due to, 95

Percutaneous transtracheal ventilation, in airway management, 21-22

Perfusion, patterns of, 2

Periodic paralysis, respiratory dysfunction in, 668-669

Petroleum distillates, poisoning due to, 99

Phenothiazine(s), acute pulmonary insufficiency due to, 98

Phosgene, inhalation injury due to, 108-109

Phrenic nerves, stimulation of, in ventilatory impairment in neuromuscular disease, 759

Physical therapy, chest, for Guillain-Barré syndrome, 710

Pitressin, in massive hemoptysis management, 158-159

Pleural effusions, in COPD patients with acute respiratory failure, 486

Pleuropulmonary disease, ergot derivatives and, 724

Pneumocystis carinii pneumonia, spontaneous pneumothorax in, 80-81

Pneumomediastinum, 86-87

Pneumonia, bacterial, CNS injury and, 743

 community-acquired, 581-592

 atypical, 586-589

 clinical features, 586-588

 described, 586

 diagnosis, 588-589

 pathogenesis, 586

 treatment, 590-591

 severe, prevention, 591-592

 treatment, 589-591

 typical, 581-586

 clinical features, 584

 described, 581

 diagnosis, 584-586

 microbiology of, 583-584

 pathogenesis, 581-583

 treatment, 590

 life-threatening, 581-602

 nosocomial, 592-598

 cellular and immunologic compromise in, 594

 clearance of aspirated secretions in, 593-594

 clinical features, 594-595

 diagnosis, 594-597

 endotracheal and nasogastric tubes in, 593

host defense mechanisms in, 593-594

increased aspiration in, 593

microbiology of, 594

oropharyngeal colonization in, 592-593

pathogenesis, 592-593

prevention, 598

treatment, 598-599

Pneumocystis carinii, spontaneous pneumothorax in, 80-81

Pneumopericardium, 88

Pneumoperitoneum, 88

Pneumothorax, 75-86

 catamenial, 80

 in chest trauma, 138

 clinical forms of, 75

 defined, 75

 drug abuse-related, 80

 iatrogenic, 81

 management, 89

 mechanical ventilation-related, 81-83

 management, 89-90

 spontaneous, in COPD patients with acute respiratory failure, 486

 primary, 77-79

 management, 89

 secondary, 79-81

 COPD in, 79-80

 management, 89

Pneumocystis carinii pneumonia in, 80-81

 tension, 85-86

 management, 89

 mechanical ventilation and, 530-532

 traumatic, 83-85

 management, 90

 types, 77

Poisonings, agents associated with, 99-100

 cyanide, treatment, 111

Polysomnography, in ventilatory impairment in neuromuscular disease, 759-760

Positive end-expiratory pressure (PEEP), for acute lung injury, 528-530

for Guillain-Barré syndrome, 711

for head and spinal cord injuries, 745

Positive pressure ventilation, in neuromuscular disease, 765-767

Prednisolone, for severe asthma, 461-462

Progressive myopathies, ventilatory support in, 773-775

Propoxyphene, respiratory insufficiency due to, 98

Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED), 550-551

Prostaglandin(s), for acute lung injury, 540

Protamine, respiratory failure due to, 95

Protected specimen brush (PSB), quantitative culture of, in nosocomial pneumonia diagnosis, 595-596

Protocols, Balke, 198-199

Brue, 198

in cardiopulmonary exercise testing, 198-200

for exercise testing in COPD, 320

for exercise testing in pulmonary rehabilitation, 334

Pulmonary artery catheterization, in acute cardiogenic pulmonary edema, 507-508

Pulmonary congestion, during exercise, in the elderly, 240

Pulmonary disease(s), chronic obstructive, spontaneous pneumothorax, 79-80

Pulmonary edema, acute cardiogenic, 501-515

 aortic insufficiency in, 507

 aortic stenosis and, 506-507

 causes, 501

 diastolic dysfunction in, 506

mitral insufficiency in, 507
 pathophysiology, 501-504
 pulmonary edema fluid sampling in, 508
 pulmonary artery catheterization in, 507-508
 radiographic evidence of, 504-505
 treatment, 508
 high-altitude (HAPE), 509-512
 in multiple sclerosis, 698-699
 neurogenic, 512-514
 CNS injury and, 742-743
 postobstructive, 512
 re-expansion, 509
 management, 90
 unusual forms of, 508-514
 valvular heart disease and, 506-507
 Pulmonary edema fluid sampling, in acute cardiogenic pulmonary edema, 508
 Pulmonary embolism, CNS injury and, 743
 incidence, 547
 massive, 547-560
 causes, 547-548
 clinical examples, 557-558
 diagnosis, 550-551
 hypotension, 556-557
 mortality due to, 547
 pathophysiology, 548-550
 treatment, 551-557
 anticoagulation, 551-553
 embolectomy, 556
 inferior vena cava filter in, 555-556
 thrombolytic therapy, 553-555
 respiratory failure in COPD due to, 484-485
 unusual forms of, 561-580
 Pulmonary function testing, in ALS, 676-679
 in Guillain-Barré syndrome, 708-710
 in ventilatory impairment in neuromuscular disease, 755-756
 Pulmonary gas exchange, in cardiopulmonary exercise testing, 208-209, 427-430
 Pulmonary gas exchange inefficiency, during exercise, 250
 Pulmonary mechanics, alterations in, CNS injury and, 742
 Pulmonary rehabilitation, exercise in, 327-337
 laboratory testing procedures, 333-335
 types, 333-334
 exercise testing in, to assess exercise limitation, 330
 to assess exercise tolerance, 329-330
 blood gas changes, 332-333
 bronchospasm due to, 333
 exercise prescription in, 330-332
 measurements for, 334-335
 protocols for, 334
 uses, 328-333
 exercise training responses in, mechanisms of, 328
 for respiratory disorders, in neuromuscular disease, 784-787
 Pulmonary system, exercise effects on, in the elderly, 229-246
 breathing pattern, 232-233
 dyspnea, 239
 gas exchange, 237-238
 mechanics of, 233-237
 pulmonary congestion, 240
 pulmonary hemodynamic response, 238-239
 respiratory muscle fatigue, 239-240
 responses, 240-241
 ventilatory response, 231-232
 in young adults, 229-230
 limitations of, to exercise performance, in the elderly, 241-243
 Pulmonary vascular disease, cardiopulmonary exercise testing for, 283-284
 Pulse oximetry, in cardiopulmonary exercise testing, 202-203
 Quality assurance, in cardiopulmonary exercise testing, 197-198
 Radiation therapy, in massive hemoptysis management, 159
 Radiography, chest, in acute cardiogenic pulmonary edema, 504-505
 in asthma, 457
 in upper airway obstruction evaluation, 45
 Reference values, in cardiopulmonary exercise testing, 209-210
 Rehabilitation, pulmonary. See *Pulmonary rehabilitation*.
 Respiration, brainstem, and Ondine's syndrome, 731-733
 defined, 1
 limbic, stroke and, 734
 voluntary controlled, stroke and, 733-734
 Respiratory disease, exertional dyspnea and, 263-264
 Respiratory distress, in the ventilated patient, 55-73. See also *Ventilation, mechanical*.
 assessment and management, 66-69
 causes, 56
 cough due to tracheal irritation and, 58
 endotracheal tube failure and, 57-58
 inspissated secretions and, 57
 paralytics for, 69-70
 recognition of, 65
 sedatives for, 69-70
 Respiratory failure, acute, abnormal diffusion in, 7
 causes, pathophysiologic, 3-8
 clinical classification, 8-10
 gas exchange in, 1-2
 hypoxia in, 4
 oxygen transport effects, 11
 $P(A-a)O_2$ in, 2-3
 pathophysiology of, 1-12
 reduction of inspired oxygen in, 7-8
 shunt in, 6-7
 treatment, 10-11
 venous admixture in, 8
 ventilation-perfusion mismatch in, 4-6
 in ALS, 675-676
 in COPD, 481-500. See also *Chronic obstructive pulmonary disease (COPD), acute respiratory failure in*.
 defined, 1
 diagnosis, 1
 drugs and, 93-102. See also *Drug(s), respiratory failure due to*.
 in Guillain-Barré syndrome, 706-707
 in myasthenia gravis, 689
 in myopathic disease, treatment, 662-663
 processes involved in, 1
 treatment, 679
 Respiratory function, assessment, 661-662
 disorders of, 661-674
 in acquired myopathies, 669-672
 in ALS, 675-681. See also *Amyotrophic lateral sclerosis (ALS), respiratory dysfunction in*.
 causes, 620-621

Respiratory function (Continued)

- CNS trauma and, 739-749. See also *Central nervous system (CNS), trauma to, respiratory dysfunction associated with*
- in Guillain-Barré syndrome, 705-714. See also *Guillain-Barré syndrome, respiratory failure in*
- inherited myopathic, 663-669
- in multiple sclerosis, 693-693. See also *Multiple sclerosis, respiratory dysfunction in*
- in myasthenia gravis, 683-691. See also *Myasthenia gravis, respiratory dysfunction in*
- in neuromuscular disease, management, 783-795
- in parkinsonism, 715-727. See also *Parkinson's disease, respiratory dysfunction in*
- in stroke, 729-737. See also *Stroke, respiratory dysfunction in*
- in Duchenne muscular dystrophy, 663-664
- overview of, 619-639
- Respiratory insufficiency, acute, drugs causing, 97-98
- Respiratory muscle(s), activity of, during exercise, 252
- blood flow in, 341
- and circulation, 626-627
- composition of, 341
- contraction patterns of, exercise in COPD and, 312-313
- coordination of, 341, 633-634
- of the diaphragm, 627-629
- disorders of, secondary effects on, 634
- evaluation, 610
- during exercise, in interstitial lung disease, 292-294
- fiber types in, 622
- function of, in ventilatory impairment in neuromuscular disease, 756-759
- impulse to inspiration, 627
- innervation of, 753
- mechanical properties of, 622-624
- metabolism of, 341
- myasthenia gravis effects on, 683-684
- neural connections of, 625, 626
- neural control and coordination of, 341-342
- as skeletal muscles, 622
- strength of, 756-757
- weakness and fatigue of, during exercise, 252
- Respiratory muscle fatigue, 624-625
- during exercise, in the elderly, 239-240
- Respiratory muscle training, in myopathies, 662
- Respiratory system, in cardiopulmonary exercise testing, 425
- components of, 619
- emergencies related to, airway management in, 13-34. See also *Airway management, in respiratory emergencies*
- issue on, 1-168, 453-602
- Rhabdomyolysis, respiratory dysfunction in, 671-672
- Rib(s), fractures of, in COPD patients with acute respiratory failure, 486
- diagnosis and treatment, 142
- Rib cage, analysis of, in ventilatory impairment in neuromuscular disease, 758-759
- Salbutamol, for severe asthma, 458-459
- Salicylates, acute lung injury due to, 523
- respiratory failure due to, 94
- Scalene muscles, 629
- Sedative(s), in airway management, 24
- for respiratory distress, 69-70
- for severe asthma, 469-471
- Sepsis syndrome, acute lung injury due to, 522
- Sex, of exercise training program participants, 224
- Shunt, physiologic, in acute respiratory failure, 6-7
- defined, 6
- Shy-Drager syndrome, 720
- Skeletal muscles, respiratory muscles as, 622
- Sleep disorders, myopathy and, 662
- and neuromuscular disease, 613-614
- in ventilatory impairment in neuromuscular disease, 752
- Slow twitch, 173
- Smoke inhalation, acrolein, 113
- clinical manifestations, 113-114
- inhalation injury due to, 112-114
- treatment, 114
- Spectrometer, mass, in cardiopulmonary exercise testing, 195
- Spinal cord, injuries of, respiratory care in, 743-744
- in ventilatory impairment in neuromuscular disease, 754
- ventilatory support in, 777-778
- Spine injury, cervical, airway management in, 25-26
- Spirometry, in Guillain-Barré syndrome, 710
- in lung resection evaluation, 389-390
- in myasthenia gravis, 684-685
- in upper airway obstruction evaluation, 44-45
- in ventilatory impairment in neuromuscular disease, 755-756
- Split lung function studies, in lung resection evaluation, 391-392
- Spontaneous pneumothorax, in COPD patients with acute respiratory failure, 486
- Sputum examination, in nosocomial pneumonia diagnosis, 595
- Starling equation, 501
- Sternomastoid muscle, 630
- Sternum, fractures of, diagnosis and treatment, 142
- Strength training, purpose of, 215
- Streptococcus pneumoniae*, respiratory failure in COPD due to, 483-484
- Streptokinase, for pulmonary embolism, 554
- Stridor, acoustic analysis of, 46
- Stroke, brainstem, 730-731
- cough and, 734
- hemispheric, 729-730
- hiccup and, 734
- limbic respiration and, 734
- respiratory dysfunction in, 729-737
- prognostic value of, 734-736
- ventilatory support in, 777
- voluntary controlled respiration and, 733-734
- Succinylcholine, in airway management, 24
- Suctioning, for head and spinal cord injuries, 744-745
- Sulfur dioxide, inhalation injury due to, 109
- Surgery, in massive hemoptysis management, 162-163
- Surrogate decision-making, in Duchenne muscular dystrophy, 792-793
- Swallowing, in ventilatory impairment in neuromuscular disease, 752
- Swan-Ganz catheters, for acute lung injury, 538-539
- Systemic lupus erythematosus (SLE), respiratory dysfunction in, 670
- Systolic dysfunction, cardiopulmonary exercise testing for, 279-280
- Tachypnea, in acute lung injury, 520
- Tension pneumothorax, mechanical ventilation and, 530-532
- Terbutaline, for severe asthma, 458
- Terfenadine, in exercise-induced asthma, 361

Tetracaine, in airway management, 23-24

Thallium-dipyridamole imaging, respiratory failure due to, 97

Theophylline, in exercise-induced asthma, 360-361

- for respiratory failure in COPD, 490-491
- for severe asthma, 459

Thoracotomy, emergency room, in chest trauma, 141

Thromboembolism, concept of, 547-548

- predisposing factors of, 548
- pulmonary, in COPD patients with acute respiratory failure, 492

Thrombolytic therapy, for pulmonary embolism, 553-555

Tissue plasminogen activator (TPA), for pulmonary embolism, 554

Tocolytic(s), respiratory failure due to, 95

Toxins, systemic, inhalation injury due to, 112

- types, 99-100

Tracheal gas insufflation, for acute lung injury, 534-535

Tracheal stenosis, intubation and, 39

Tracheobronchial injuries, diagnosis and treatment, 144-145

Tracheoesophageal fistula, respiratory distress due to, 58

Tracheostomy, emergency, in airway management, 22-23

- for Guillain-Barré syndrome, 711

Tracheostomy tube, malposition of, respiratory distress due to, 56-57

Tracheotomy, airway injury following, 39-40

Transdiaphragmatic pressure, in ventilatory impairment in neuromuscular disease, 757-758

Transplantation, heart, cardiopulmonary exercise testing for, 280-282

- heart-lung, exercise limitation in, 416-418
- exercise testing in, 415-416
- guidance provided by, 418-419
- lung. *See Lung transplantation.*

Transthoracic needle aspiration, in nosocomial pneumonia diagnosis, 596-597

Trapezius muscle, 632

Trauma, airway management in, 25-28

- chest, 137-146. *See also Chest trauma.*
- airway management in, 27-28

craniofacial, airway management in, 26-27

great vessel, diagnosis and treatment, 143-144

pneumothorax associated with, 83-85

spinal, airway management in, 25-26

Treadmill, in cardiopulmonary exercise testing, 193-194

- protocols in, 198-199

Triangular sternal muscles, 631-632

Tuberculosis, massive hemoptysis due to, 148-149

Tumor(s), massive hemoptysis due to, 151-152

- upper airway obstruction due to, 44

Tumor embolism, 568-569

Turbine, in cardiopulmonary exercise testing, 195

Urokinase, for pulmonary embolism, 554

Valvular heart disease, pulmonary edema due to, 506-507

Vasoconstrictive agents, in massive hemoptysis management, 158-159

Vasodilator(s), for acute lung injury, 540

Vecuronium, in airway management, 24

Venous admixture, in acute respiratory failure, 8

- described, 8

Venous air embolism, 570-574

causes, 570-571

clinical manifestations, 572

diagnosis, 572

pathophysiology, 571-572

treatment, 572-574

Ventilation, alveolar, increased, during exercise, 250

- artificial, for respiratory failure, in ALS, 679-680
- control of, in Parkinson's disease, 718-719
- endotracheal, for severe asthma, 463-465
- during exercise, in interstitial lung disease, 288-290
- exercise in COPD and, 308-309
- in exercise testing in pulmonary patients, 335
- high-frequency, for acute lung injury, 535
- inverse-ratio, for acute lung injury, 534
- measurements of, in noninvasive cardiopulmonary exercise testing, 278
- mechanical, for acute cardiogenic pulmonary edema, 508
- for acute lung injury, 528-530
- alveolar rupture due to, 530-532
- artificial airway problems in, 56-59
- asynchrony due to, 61-62
- auto-PEEP due to, 62-64
- barotrauma due to, 64-65, 530-532
- in COPD patients with acute respiratory failure, complications, 493
- dynamic hyperinflation due to, 62-64
- external ventilator circuit complications, 59-60
- goals of, 55
- for head and spinal cord injuries, 746
- lung injury associated with, 530-532
- machine malfunction, 60-61
- for neuromuscular disease, 765-781. *See also specific types of ventilation.*
- indications for, 770-771
- initiation of, 772-773
- mechanisms of action of, 769-770
- monitoring and follow-up, 773
- withdrawal of, 791-792

patient-ventilator system problems, 61-65

pneumothorax associated with, 81-83

- management, 89-90
- problems related to, 55-65
- respiratory distress during, 55-73. *See also Respiratory distress, in the ventilated patient.*
- causes, 56
- for respiratory failure in COPD, 493-495
- for severe asthma, 465-469
- tension pneumothorax due to, 530-532

negative pressure, in neuromuscular disease, 767-768

in neuromuscular disease, 607-617

patterns of, 2

positive pressure, in neuromuscular disease, 765-767

pressure-controlled, for acute lung injury, 534

pulmonary, exercise training effects on, 218

unilateral lung, in massive hemoptysis management, 159-160

Ventilation-perfusion mismatch, in acute respiratory failure, 4-6

Ventilators, abdominal displacement, in neuromuscular disease, 768-769

- complications, 60-61
- external circuit, respiratory distress due to, 59-60
- in neuromuscular disease, selection of, 771-772

Ventilatory failure, 10

- assessment, in neuromuscular disease, 751-763
- history in, 752-753
- laboratory evaluation, 755-761
- physical examination in, 753-755

Ventilatory response, to exercise testing, 184-186

Ventilatory response (*Continued*)
in neuromuscular disease, 611
reduced, in neuromuscular disease, 611-612
Ventilatory support, long-term, ethical and legal issues
in, 787-789
for respiratory failure in myopathic disease, 662-663
Vocal-cord dysfunction, functional, upper airway
obstruction due to, 41
Volume at end-expiration (V_{EE}), 466
Volume at end-inspiration (V_{II}), 466

Washington University/Barnes Hospital, lung
transplantation at, exercise testing in, 406-415
Water loss, exercise-induced asthma due to,
353-354
Wheezing, in asthma, 455

Zirconium electrochemical cell, in cardiopulmonary
exercise testing, 195

